cjc+ipa blend vs tesamorelin

cjc+ipa blend (A-tier) vs tesamorelin (S-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

cjc+ipa blend — tier A

clinic-standard GH-axis pairing. cjc-1295 + ipamorelin. receptor logic first, blend trial evidence still thin.

the most common peptide-clinic GH-axis stack. CJC-1295 + ipamorelin amplifies pulse amplitude through two separate receptors.

PCAC '24 503A excluded · half-life CJC-1295: 30 min (no DAC); ipamorelin: ~2 h · growth hormone

tesamorelin — tier S

the FDA-approved injection that targets visceral fat. the dangerous kind.

the only adult-labeled GHRH analog. FDA-approved for visceral fat reduction in HIV-associated lipodystrophy. the label says it's not a weight-loss drug.

15-18% VAT reduction · half-life ~26-38 minutes (subQ) · weight loss

at a glance

• cjc+ipa blend: tier A · PCAC '24 503A excluded
• tesamorelin: tier S · 15-18% VAT reduction

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.